It is the best-selling drug in France: Doliprane, a small pill that is effective in treating migraines. It is manufactured by Opella, a subsidiary of the French laboratory Sanofi… but this subsidiary will go under the American flag. Its takeover has been the subject of a soap opera in France for several weeks. Faced with the employees' strike, the State got involved and will become a minority shareholder.
The reindustrialization of France is a stated priority of President Emmanuel Macron. Opening of factories, gigafactories, investments in shambles… but already, this project seems to be running out of steam. What is it really? Is France's industrial sovereignty an illusion? Can the country be competitive in the face of European and international competition?
To debate it :
-Vincent Charletgeneral delegate of the think tank The Industry Factory
– Sébastien Martin, president of the Grand Chalon urban community, president of Intercommunalités de France
– Anaïs Voy-Gillis, doctor in geography, specialist in industrial issues, associate researcher at the Institute of Business Administration and author of Towards the industrial renaissanceMarie B editions.
France
